You Be the Judge!
To prevail on a hostile work environment claim, a plaintiff must prove that the workplace was permeated with discriminatory intimidation that was "sufficiently severe or pervasive to alter the conditions" of employment. <i>Meritor Savings Bank FSB v. Vinson</i>, 477 U.S. 57, 106 S.Ct. 2399 (1986) An objectionable environment must be "both objectively and subjectively offensive, one that a reasonable person would find hostile and abusive, and one that the victim in fact did perceive to be so." <i>Faragher v. City of Boca Raton</i>, 524 U.S.775, 118 S.Ct. 2275, 2283 (1998). Courts must examine the totality of the circumstances in deciding whether a hostile environment exists. <i>Id</i>.
Med-Mal Cases Down - Is 'Tort Reform' the Cause?
The 15 medical malpractice cases in the Top 100 jury verdicts of 2003 were a mixed bag of tragedies that may (or may not) have been affected by efforts to limit tort rights. The verdicts totaled $545.5 million. While that is a robust sum, it is nearly $178.6 million less than in the previous year's top verdicts, even though 2003 had two additional cases. Some attorneys and med-mal experts contend that trend-spotting is a pointless parlor game leading to faulty conclusions. Verdicts are fact-driven, they say. Others see shrinking verdicts and blame "tort reform," which, they say, includes damage caps in 27 states and indirectly affects juries everywhere.
Expert Witness Liability: An Expanding Field
Expert witnesses have become a necessity in virtually all litigation, from medical malpractice to products liability to family law cases. Technical understanding of disputes is required for juror determination in this increasingly technical world. Damages need to be calculated using expert data; professional standards and their application to any medical malpractice action require expert opinion. But what happens when the side hiring the expert loses, or the independent evaluation doesn't come up with the hoped-for answer? Increasingly, what happens is the disappointed party sues the expert. In some cases, the experts have immunity to lawsuit, but in an increasing number of instances, they simply do not.
Features
When to Conduct Voir Dire of Expert Witnesses
Last month, we discussed tactical considerations when challenging expert witnesses' qualifications. This month, we focus on the optimal time to conduct <i>voir dire</i>.
Features
Med Mal News
National news of interest to you and your practice.
Recent Developments from Around the States
National cases of interest to your practice.
Recent Developments in Executive Compensation
Although executive compensation has been the subject of evolving reform for several years, the bright spotlight of public attention is now focused on this issue, due in part to the bursting of the stock market bubble, the collapse of Enron, and a number of other highly publicized corporate scandals. The image of executives enjoying excessive compensation packages as revenues and earnings decline, and stock values of the companies they manage plummet, is a dangerously common stereotype.
Features
Bullies in the Workplace
Bullying isn't just a playground issue. In an era of declining unionization, job insecurity, and the global profit squeeze, bullying has become a serious workplace problem, even though workplace bullies usually prefer memos, informal disciplinary meetings and grinding criticism to spitballs. Left unchecked, on-the-job abuse adversely affects both employers and employees. Current legal theories, though, are inadequate to address this recent phenomenon.
Features
National Litigation Hotline
Recent cases of importance to your practice.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- Surveys in Patent Infringement Litigation: The Next FrontierMost experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.Read More ›
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- In the SpotlightOn May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug & Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.Read More ›
